Floatz logo

Nintedanib

Lung Neoplasms

University Hospital, LimogesSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Lung Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Rivoceranib
Fuzhou General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Nintedanib is also rated in:

idiopathic pulmonary fibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →